Breakthrough: FDA Approves First Drug for Liver Disease Scarring – Rezdiffra Offers Hope for Millions
Washington, D.C. – The U.S. Food and Drug Administration (FDA) recently granted approval for a groundbreaking treatment for individuals suffering from a severe liver condition. The medication, known as Rezdiffra (resmetirom), is designed to address nonalcoholic steatohepatitis (NASH), a form of liver inflammation commonly linked to fatty liver disease. NASH, also referred to as metabolic dysfunction-associated steatohepatitis (MASH), is characterized by liver inflammation caused by an accumulation of fatty cells. If left untreated, NASH can …